Senate approves HOPE Treatment Act to let Tennessee join interstate ibogaine trials

The Tennessee Senate passed Senate Bill 21-49, known on the floor as the HOPE Treatment Act, creating a council to oversee participation in emerging behavioral health clinical trials and establishing an emerging behavioral health treatment innovation fund.

Chairman Watson explained that amendment language "enacts the HOPE Treatment Act" and allows Tennessee to participate in multi-state ibogaine clinical trials through a public-private consortium. He said participating institutions must submit quarterly reports and verify matching funds, and the treasurer would deposit at least 50% of state revenue from any future FDA-approved medication developed into the fund.

Sponsor Senator Wally urged support, saying the measure provides "hope" for Tennessee veterans and others suffering opioid use disorder and PTSD, noting that the trial option would not require state funding. "This multi state public private partnership is going to allow Tennessee to participate in this consortium," he said, adding it could offer life-changing outcomes for some patients.

Floor debate included brief procedural questions but no recorded opposition sufficient to block passage. The Senate approved the bill on third reading (ayes 29, nays 1) and declared it passed without objection.

Next steps: The bill's administrative details — application periods for qualified institutions, quarterly reporting, and fund administration — will move to rulemaking and implementation by relevant agencies if enacted.